Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 16,456 as of Friday, Jan. 3, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,718 issues advancing vs. 1,181 declining with 172 unchanged. The Health Care sector currently sits up 0.4% versus the S&P 500, which is unchanged. Top gainers within the sector include Agilent Technologies ( A), up 1.5%, Bristol-Myers Squibb Company ( BMY), up 1.2%, Novo Nordisk A/S ( NVO), up 1.2%, Allergan ( AGN), up 1.1% and Johnson & Johnson ( JNJ), up 0.8%. On the negative front, top decliners within the sector include Herbalife ( HLF), down 5.3%, Biogen Idec ( BIIB), down 1.6%, Celgene Corporation ( CELG), down 1.3%, Amgen ( AMGN), down 1.1% and Gilead ( GILD), down 1.0%. TheStreet would like to highlight 5 stocks pushing the sector higher today: 5. Covidien ( COV) is one of the companies pushing the Health Care sector higher today. As of noon trading, Covidien is up $0.52 (0.8%) to $67.94 on light volume. Thus far, 325,400 shares of Covidien exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $67.30-$67.97 after having opened the day at $67.48 as compared to the previous trading day's close of $67.42. Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $30.8 billion and is part of the health services industry. Shares are unchanged year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 1 rates it a hold. TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Ikaria, which focuses on therapies for critically ill infants, is privately owned by a group led by Madison Dearborn Partners. Buyer Mallinckrodt specializes in diagnostic radiology and pain management.